News
Sarepta Therapeutics lays off 493 workers amid FDA probe, stock drop, and concerns over its gene therapy treatment, Elevidys.
When three patients die after taking a cutting-edge drug, most companies hit the brakes. Not Sarepta Therapeutics. The ...
The death of a third patient tied to a Sarepta Therapeutics gene therapy this year sent the company’s shares nosediving 36% Friday, halting the momentum the stock generated just a day earlier after ...
Drugmaker Sarepta Therapeutics said late Friday it will not comply with a request from the Food and Drug Administration to ...
Sarepta Therapeutics announced late Friday evening that it will not comply with the Food and Drug Administration's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results